SEC filings and other documents

Q2 revenue up 2.7%, adjusted EPS $1.55, and merger with Curium valued up to $8B announced.

TruVu launches regionally in late 2024, expanding PYLARIFY access and driving market growth.

Isotope innovation and robust supply chains drive PET imaging growth and new product launches.

Q1 2026 saw robust execution, regulatory progress, and reaffirmed guidance for sustained growth.

Transition to new radiodiagnostics and operational focus set up for growth in 2026 and beyond.

Strategic focus shifts to diagnostics, with new launches and disciplined capital allocation ahead.

2026 revenue guidance set at $1.4–$1.45B, with new launches to drive growth from 2027.

Q3 revenue rose 1.4% to $384M; guidance narrowed upward amid leadership transition.

Product innovation, pipeline expansion, and strategic deals position for strong growth ahead.

Q2 revenue and EPS guidance cut amid PSMA PET pricing pressure; new products and buyback announced.

Blockbuster imaging agents and new launches drive double-digit growth outlook for 2026.

PYLARIFY and radioligand therapy drive growth amid evolving reimbursement and global expansion.

Market leadership, strategic acquisitions, and a diversified pipeline drive sustained growth.

Q1 revenue up slightly; SPECT divestiture and acquisitions set stage for 2026 double-digit growth.